Effects of endostatin on C6 glioma-induced edema

Chinese Medical Journal

Volumn 124, Issue 24, 2011, Pages 4211-4216

  Yang, Li Juan ^a   Lin, Zhi Xiong ^a   Kang, De Zhi ^a   Weng, Shen Mei ^a   Lin, Jian Hua ^a   Huang, Qiang ^b   Zhang, Peng Fei ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Angiogenesis; Edema; Endostatin; Glioma; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; GLIOMA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; EDEMA; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; MALE; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862936304     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.24.017     Document Type: Article

References (27)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
2. Papadopoulos MC, Saadoun S, Davies DC, Bell BA. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001; 15: 101-108.
3. Wick W, Küker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 2004; 27: 261-266.
4. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
5. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27: 2542-2552.
6. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-620.
7. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258-1260.
8. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, et al. Endostatin reduces vascularization blood flow, and growth in a rat gliosarcoma. Neurol Oncol 2002; 4: 1-8.
9. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 2004; 10: 1255-1262.
10. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19: 35-39.
11. Eisterer W, Jiang X, Bachelot T, Pawliuk R, Abramovich C, Leboulch P, et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 2002; 5: 352-359.
12. Zheng MJ. Endostatin derivative angiogenesis inhibitors. Chin Med J 2009; 122: 1947-1951.
13. Yang LJ, Lin ZX, Lin JH, Weng SM, Huang Q, Zhang PF, et al. Antitumor effect of endostatin overexpressed in C6 glioma cells is associated with the down-regulation of VEGF. Int J Oncol 2011; 38: 465-471.
14. Lin ZH, Yang LJ, Huang Q, Lin JH, Ren J, Chen ZB, et al. Inhibition of tumor-induced edema by antisense VEGF is mediated by suppressive vesiculo-vascuolar organelles (VVO) formation. Cancer Sci 2008; 99: 2540-2546.
15. Huang F, Xi G, Keep R, Hua Y, Nemoianu A, Hoff J. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg 2002; 96: 287-293.
16. Thorsen F, Ersland L, Nordli H, Enger PO, Huszthy PC, Lundervold A, et al. Imaging of experimental rat gliomas using a clinical MR scanner. J Neurooncol 2003; 63: 225-231.
17. Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, et al. Intraocular expression of endostatin reduces VEGF-inducedretinalvascular permeability, neovascularization, and retinal detachment. FASEB J 2003; 17: 896-898.
18. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003; 536: 19-24.
19. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
20. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
21. Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 2002; 97: 839-845.
22. Oga M, Takenaga K, Sato Y, Nakajima H, Koshikawa N, Osato K, et al. Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol 2003; 23: 73-79.
23. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000; 60: 5410-5413.
24. Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H, et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008.
25. Ren B, Hoti N, Rabasseda X, Wang YZ, Wu M. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003; 25: 215-224.
26. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9: 444-453.
27. de Groot JF, Fuller G, Kumar AJ, Piao YJ, Eterovic K, Ji YJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233-242.